循环肿瘤标志物在脑胶质瘤的研究进展
摘要
脑胶质瘤是常见的原发性中枢神经系统肿瘤,发病率呈逐年上升趋势,机体状态较差及高级别脑胶质瘤病人预后较差,因此寻找能够早期诊断、判断预后及指导治疗的方法至关重要。目前,研究人员发现一些与脑胶质瘤发生、发展、预后及治疗靶点密切相关的循环肿瘤标志物。本文就循环肿瘤标志物在脑胶质瘤中的研究进展作一综述。
引文
[1]OSTROM Q T,GITTLEMAN H,STETSON L,et al.Epidemiology of gliomas[J].Cancer Treat Res,2015,163(3):1-14.
[2]SCHWARZENBACH H,HOON D S,PANTEL K.Cell-free nucleic acids as biomarkers in cancer patients[J].Nat Rev Cancer,2011,11(6):426-437.
[3]PARSONS D W,JONES S,ZHANG X,et al.An integrated genomic analysis of human glioblastoma multiforme[J].Science,2008,321(5897):1807-1812.
[4]YAN H,PARSONS D W,JIN G,et al.IDH1 and IDH2mutations in gliomas[J].N Engl J Med,2009,360(8):765-773.
[5]SALKENI M A,ZARZOUR A,ANSAY T Y,et al.Detection of EGFRv III mutant DNA in the peripheral blood of brain tumor patients[J].J Neurooncol,2013,115(1):27-35.
[6]SHINOJIMA N,TADA K,SHIRAISHI S,et al.Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme[J].Cancer Res,2003,63(20):6962-6970.
[7]CANKOVIC M,NIKIFOROVA M N,SNUDERL M,et al.The role of MGMT testing in clinical practice:a report of the association for molecular pathology[J].J Mol Diagn,2013,15(5):539-555.
[8]WEILER M,HARTMANN C,WIEWRODT D,et al.Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide[J].Int J Radiat Oncol Biol Phys,2010,77(3):670-676.
[9]WAKABAYASHI T,NATSUME A,HATANO H,et al.p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas[J].Neurosurgery,2009,64(3):455-462.
[10]LAVON I,REFAEL M,ZELIKOVITCH B,et al.Serum DNA can define tumor-spec ific genetic and epigenetic markers in gliomas of various grades[J].Neuro Oncol,2010,12(2):173-180.
[11]ROMBOS A,EVANGELOPOULU-KATSIRI E,MARIATOS P,et al.Cerebrospinal fluid carcinoembryonic antigen and alphafetoprotein in patients with central nervous system neoplasia[J].Acta Neurol Scand,1988,77(6):440-444.
[12]RAPOSO G,NIJMAN H W,STOORVOGEL W,et al.B lymphocytes secrete antigen-presenting vesicles[J].J Exp Med,1996,183(3):1161-1172.
[13]TUMILSON C A,LEA R W,ALDER J E,et al.Circulating micro RNA biomarkers for glioma and predicting response to therapy[J].Mol Neurobiol,2014,50(2):545-558.
[14]YANG C,WANG C,CHEN X,et al.Identification of seven serum micro RNAs from a genome-wide serum micro RNA expression profile as potential noninvasive biomarkers for malignant astrocytomas[J].Int J Cancer,2013,132(1):116-127.
[15]ROTH P,WISCHHUSEN J,HAPPOLD C,et al.A specific mi RNA signature in the peripheral blood of glioblastoma patients[J].J Neurochem,2011,118(3):449-457.
[16]WONG E T,ALSOP D,LEE D,et al.Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas[J].Cerebrospinal Fluid Res,2008,5(1):1.
[17]IWAMOTO F M,HOTTINGER A F,KARIMI S,et al.Longitudinal prospective study of matrix metalloproteinase-9as a serum marker in gliomas[J].J Neurooncol,2011,105(3):607-612.
[18]LYUBIMOVA N V,TOMS M G,POPOVA E E,et al.Neurospecific proteins in the serum of patients with brain tumors[J].Bull Exp Biol Med,2011,150(6):732-734.
[19]WEI P,ZHANG W,YANG L S,et al.Serum GFAP autoantibody as an ELISA-detectable glioma marker[J].Tumour Biol,2013,34(4):2283-2292.
[20]IWAMOTO F M,HOTTINGER A F,KARIMI S,et al.Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas[J].Neuro Oncol,2011,13(11):1244-1251.
[21]杨帅,王伟民,张小鹏,等.血清YKL-40水平与胶质瘤病理分级及预后的相关性研究[J].中国微侵袭神经外科杂志,2014,19(10):437-439.
[22]何主强,殷莉,赵洪洋.骨桥蛋白与整合素β3在脑胶质瘤中的表达及其意义[J].中国微侵袭神经外科杂志,2005,10(11):508-511.
[23]DAWAR R,FABIANO A J,QIU J,et al.Secondary gliosarcoma with extra-cranial metastases:a report and review of the literature[J].Clin Neurol Neurosurg,2013,115(4):375-380.
[2]SCHWARZENBACH H,HOON D S,PANTEL K.Cell-free nucleic acids as biomarkers in cancer patients[J].Nat Rev Cancer,2011,11(6):426-437.
[3]PARSONS D W,JONES S,ZHANG X,et al.An integrated genomic analysis of human glioblastoma multiforme[J].Science,2008,321(5897):1807-1812.
[4]YAN H,PARSONS D W,JIN G,et al.IDH1 and IDH2mutations in gliomas[J].N Engl J Med,2009,360(8):765-773.
[5]SALKENI M A,ZARZOUR A,ANSAY T Y,et al.Detection of EGFRv III mutant DNA in the peripheral blood of brain tumor patients[J].J Neurooncol,2013,115(1):27-35.
[6]SHINOJIMA N,TADA K,SHIRAISHI S,et al.Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme[J].Cancer Res,2003,63(20):6962-6970.
[7]CANKOVIC M,NIKIFOROVA M N,SNUDERL M,et al.The role of MGMT testing in clinical practice:a report of the association for molecular pathology[J].J Mol Diagn,2013,15(5):539-555.
[8]WEILER M,HARTMANN C,WIEWRODT D,et al.Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide[J].Int J Radiat Oncol Biol Phys,2010,77(3):670-676.
[9]WAKABAYASHI T,NATSUME A,HATANO H,et al.p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas[J].Neurosurgery,2009,64(3):455-462.
[10]LAVON I,REFAEL M,ZELIKOVITCH B,et al.Serum DNA can define tumor-spec ific genetic and epigenetic markers in gliomas of various grades[J].Neuro Oncol,2010,12(2):173-180.
[11]ROMBOS A,EVANGELOPOULU-KATSIRI E,MARIATOS P,et al.Cerebrospinal fluid carcinoembryonic antigen and alphafetoprotein in patients with central nervous system neoplasia[J].Acta Neurol Scand,1988,77(6):440-444.
[12]RAPOSO G,NIJMAN H W,STOORVOGEL W,et al.B lymphocytes secrete antigen-presenting vesicles[J].J Exp Med,1996,183(3):1161-1172.
[13]TUMILSON C A,LEA R W,ALDER J E,et al.Circulating micro RNA biomarkers for glioma and predicting response to therapy[J].Mol Neurobiol,2014,50(2):545-558.
[14]YANG C,WANG C,CHEN X,et al.Identification of seven serum micro RNAs from a genome-wide serum micro RNA expression profile as potential noninvasive biomarkers for malignant astrocytomas[J].Int J Cancer,2013,132(1):116-127.
[15]ROTH P,WISCHHUSEN J,HAPPOLD C,et al.A specific mi RNA signature in the peripheral blood of glioblastoma patients[J].J Neurochem,2011,118(3):449-457.
[16]WONG E T,ALSOP D,LEE D,et al.Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas[J].Cerebrospinal Fluid Res,2008,5(1):1.
[17]IWAMOTO F M,HOTTINGER A F,KARIMI S,et al.Longitudinal prospective study of matrix metalloproteinase-9as a serum marker in gliomas[J].J Neurooncol,2011,105(3):607-612.
[18]LYUBIMOVA N V,TOMS M G,POPOVA E E,et al.Neurospecific proteins in the serum of patients with brain tumors[J].Bull Exp Biol Med,2011,150(6):732-734.
[19]WEI P,ZHANG W,YANG L S,et al.Serum GFAP autoantibody as an ELISA-detectable glioma marker[J].Tumour Biol,2013,34(4):2283-2292.
[20]IWAMOTO F M,HOTTINGER A F,KARIMI S,et al.Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas[J].Neuro Oncol,2011,13(11):1244-1251.
[21]杨帅,王伟民,张小鹏,等.血清YKL-40水平与胶质瘤病理分级及预后的相关性研究[J].中国微侵袭神经外科杂志,2014,19(10):437-439.
[22]何主强,殷莉,赵洪洋.骨桥蛋白与整合素β3在脑胶质瘤中的表达及其意义[J].中国微侵袭神经外科杂志,2005,10(11):508-511.
[23]DAWAR R,FABIANO A J,QIU J,et al.Secondary gliosarcoma with extra-cranial metastases:a report and review of the literature[J].Clin Neurol Neurosurg,2013,115(4):375-380.